@Datamonitor_HC

Datamonitor Healthcare provides timely, in-depth analysis of the pharmaceutical and biotechnology industries

citeline.com/en/products-services/commercialization/datamonitor-healthcare
Joined July 2012
  • Tweets3.3K
  • Following686
  • Followers1.3K
1.1KMedia
One of our senior epidemiologists, Hannah Sally, recently spoke to Verywell Health about vaccine effectiveness - see more here: bit.ly/3yItZ4D #Covid19 #vaccines #longcovid #Pharmaceuticals
2
The approval of #aducanumab gives much-needed hope to patients with #Alzheimers disease and their families Our expert, Pamela Spicer, rounds out her interview series with @Pharmacy_Times: bit.ly/3ydMqxR #Pharma #Healthcare #Pharmacy #Pharmaceuticals

Expert: Approval of Aducanumab for Alzheimer Disease 'Is a Huge Accomplishment' | Pharmacy Times

Because there are no other available treatment options, Pamela Spicer said the approval of aducanumab gives much-needed hope to patients with Alzheimer disease and their families.

pharmacytimes.com
In an interview with @Pharmacy_Times, Pamela Spicer, our senior analyst, said the various controversies surrounding the @US_FDA approval of #aducanumab could impact its implementation in health systems: bit.ly/3zKOE8m #Alzheimers #Pharma #healthcare

Expert: Aducanumab Concerns Could Impact Implementation for Alzheimer Disease | Pharmacy Times

Although she said it is unlikely that the FDA will retract the approval, prescribers could be reluctant to administer aducanumab to patients.

pharmacytimes.com
1
In an interview with @Pharmacy_Times, Pamela Spicer, our senior analyst at @Pharma_Intell, reviewed the 2 pivotal phase 3 clinical trials supporting the @US_FDA's recent approval of #aducanumab. Watch the interview: bit.ly/3iudSRq #Alzheimers #Pharmacy #fda

A Review of Data Supporting the Approval of Aducanumab for Alzheimer Disease | Pharmacy Times

Findings from the 2 pivotal phase 3 trials had mixed results on cognitive benefit, although they found a positive reduction in amyloid plaque in patients' brains.

pharmacytimes.com
The @US_FDA approval of #aducanumab for the treatment of patients with #Alzheimers has been debated, Pamela Spicer, our senior analyst, said its approval is a momentous occasion for this patient population when she spoke to @Pharmacy_Times: bit.ly/2V4zvzy

Expert: Aducanumab Approval Creates Hope, New Opportunities for Patients with Alzheimer Disease |...

Pamela Spicer, senior analyst at Datamonitor with Informa Pharma Intelligence, said there are no other currently available treatments for Alzheimer disease that get to the root of the condition.

pharmacytimes.com
*Free E-Book* In #2020 the top 10 pharmaceuticals' revenues surpassed $100 Billion. Despite #Covid19 all but one has proved to be truly pandemic-proof and achieve growth: bit.ly/36cWISq #pharma #pharmaceuticals #drugpricing #drugdevelopment
*In the News* Pamela Spicer speaks all things Alzheimer's!!! Pamela Spicer is our senior analyst with Datamonitor Healthcare and recently interviewed with @Pharmacy_Times. Check it out: bit.ly/3BcTtc0 #alzheimers #pharmacy #healthcare @Pharma_Intell

An Overview of Aducanumab for the Treatment of Alzheimer Disease | Pharmacy Times

Pamela Spicer, senior analyst with Datamonitor Healthcare, said aducanumab is a once-monthly infusion with a 6-month titration schedule.

pharmacytimes.com
1
*Free E-Book* In #2020 the top 10 pharmaceuticals' revenues surpassed $100 Billion. Despite #Covid19 all but one has proved to be truly pandemic-proof and achieve growth: bit.ly/3qOfRE3 #pharma #pharmaceuticals #drugpricing #drugdevelopment
1
Understand #drugdevelopment risk profiles & assess competitive landscapes to help give your clients the most informed perspective with #PharmaIntelligence Financial Services Suite. Request a demo here bit.ly/2QZtq5z
Is the data informing your strategy up to date? Is it customized to your market? If not, find out more about how @Pharma_Intell #FinancialServices can help you. Learn more here bit.ly/2RAKIGK
Get global #pipeline trial data, disease & clinical data analysis & more with the #FinancialServices suite from #PharmaIntelligence. Click to request a free demo bit.ly/3vqpaLn
Get unique competitor insights in #pharma with our detailed reviews of #clinicaltrials and ability to track all drugs in development with the #FinancialServices suite from #PharmaIntelligence. Get your demo here today bit.ly/3eBiOlF
With forward-looking perspectives that include catalyst tracking & regulatory success metrics. Think ahead with the #FinancialServices Suite from #PharmaIntelligence. Request a free demo here bit.ly/3vqTh5c
Think ahead with the #FinancialServices Suite from @Pharma_Intell and respond to market events & anticipate changes by tracking updates that impact the #pharma industry. Learn more here bit.ly/32RjEFj
Get expert analysis on #clinical development success rates covering 2011-2020, including comparisons of success rates across indications & modalities. Download your copy here bit.ly/2MNgbDd
Get access to the latest report on industry #clinical success rates developed by expert from BIO, #PharmaIntelligence & #QLSAdvisors. Download your free report here bit.ly/3kJMUGc
Did you know that #HPV 16 & 18 are responsible for causing around 70% of all #cervicalcancers globally? Learn more in our latest #disease analysis reports from the #ReportStore bit.ly/2YsDOTM
Stay up to date with the latest insights & news from #PharmaIntelligence with our #podcasts. Now available on all major streaming channels. Click here to find out more & start listening! bit.ly/3rfb1hY
Looking to stay up to date with the latest insights & news from #PharmaIntelligence? Subscribe to our #podcasts. Now available on #Spotify! spoti.fi/362LNem
1
Today is #WorldAidsDay which raises awareness of the millions living with #HIV & #AIDS. We are offering 20% off reports including our indepth #disease analysis & forecast until 2027 report. Click here to take advantage of this offer bit.ly/2JnvBwc
Load more